Curis Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick Facts

By RTTNews Staff Writer ✉ | Published: 1/17/2018 7:07 AM ET

Curis, Inc. (CRIS) announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available small molecule inhibitor of the IRAK4 kinase, for treatment of patients with lymphoma. The Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CA-4948; identify any dose-limiting toxicities; and establish the recommended Phase 2 dose for the treatment of patients with lymphomas.

CA-4948 was discovered at Aurigene and is the second licensed program from the Curis-Aurigene collaboration to enter the clinic.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In June 2020

Countries that tamed coronavirus

The 1918 Spanish Flu Pandemic

Editors Pick

Germany Approves EUR 9 Bln Rescue Package For Lufthansa

The German government has approved a 9 billion euros rescue package for Deutsche Lufthansa AG (DLAKF, DLAKY), which is the largest German corporate rescue package since the coronavirus crisis struck. The airline has also agreed to the rescue deal.

Seat Distancing In JetBlue Until July

JetBlue Airways said it will continue to block middle seats in rows where passengers are not traveling together through the July 4 holiday. JetBue will block middle seats on its Airbus aircraft, while it will block aisle seats on its smaller Embraer 190 aircraft. Customers traveling together will be allowed to sit in the middle and aisle seats.

New Hoque And Sons Recalls Radhuni Curry Powder

The U.S. Food and Drug Administration or FDA announced on its website that New Hoque and Sons, Inc. is recalling Radhuni Curry Powder distributed in New York City, New York due to potential Salmonella contamination. The recall was made after it was found that the finished products contained several strains of Salmonella, the company said.